Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Type 2 on Insulin Clear all
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

NCT00143338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Fresno, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2008 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

NCT02871882
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obese, Overweight
Interventions
Gastric Emptying test, Mixed Oral Glucose Tolerance test, Conjugated bile acids sodium, Placebo
Radiation · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes

NCT02033499
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
SMBG
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 8, 2026, 2:00 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes

NCT00228904
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog)
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 8, 2026, 2:00 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes

NCT00228878
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Effects of Pulsatile IV insulin on Diabetic Quality of Life
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

NCT01768559
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
46
States / cities
Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

NCT06323161
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Fresno, California • Northridge, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 8, 2026, 2:00 AM EDT
Recruiting Not applicable Interventional

Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy

NCT06814184
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
app-based nurse-led virtual diabetes care
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Not applicable Interventional

Effect of Egg Consumption on Cardiometabolic Health in Prediabetic Subjects.

NCT03332927
View directory record Official record
Conditions
PreDiabetes
Interventions
Egg based breakfast foods, Non-egg based breakfast foods
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

NCT02128932
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
136
States / cities
Birmingham, Alabama • Ozark, Alabama • Tuscumbia, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Testosterone Replacement in Men With Diabetes and Obesity

NCT01127659
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 8, 2026, 2:00 AM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 8, 2026, 2:00 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

NCT03883412
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Exercise, Liraglutide
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 8, 2026, 2:00 AM EDT
Recruiting Not applicable Interventional

The Acute T-Rex (Timing of Resistance Exercise) Study

NCT06366399
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Glucose Intolerance, Sleep Disturbance, Overweight or Obesity, Insulin Sensitivity
Interventions
Resistance Exercise Timing
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
50 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mg, Placebo tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
17,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
234
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 8, 2026, 2:00 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Lycopene and Isoflavones on Glucose Metabolism

NCT01377961
View directory record Official record
Conditions
Metabolic Syndrome, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks, Screening, OGTT, Anthropometrics and Blood pressure, Blood Drawing
Drug · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 8, 2026, 2:00 AM EDT
Recruiting Phase 2 Interventional

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

NCT05499702
View directory record Official record
Conditions
Type2diabetes
Interventions
Caloric Restriction, Hyperglycemic clamp
Behavioral · Drug
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

NCT01498185
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Chula Vista, California • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 8, 2026, 2:00 AM EDT
Completed Not applicable Interventional

Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic, and Health Outcomes Among Latinos

NCT01299844
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Diabetes Peer Counseling
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
22 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2011 · Synced Oct 8, 2026, 2:00 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 8, 2026, 2:00 AM EDT